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Abstract 
Xenobiotic safety assessment is an area that impacts a multitude of different industry sectors such as 
medicinal drugs, agrochemicals, industrial chemicals, cosmetics and environmental contaminants. As such 
there are a number of well-developed in vitro, in vivo and in silico approaches to evaluate their properties and 
potential impact on the environment and to humans. Additionally, there is the continual investment in 
multidisciplinary scientists to explore non-animal surrogate technologies to predict specific toxicological 
outcomes and to improve our understanding of the biological processes regarding the toxic potential of 
xenobiotics. Here we provide a concise, critical evaluation of a number of in vitro systems utilised to assess 
hepatotoxic potential of xenobiotics.  
Keywords; in vitro toxicology, drug safety, hepatotoxicity, 3D cell culture models, liver spheroids,  
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Introduction 
The major constituent cell type of the liver is the hepatocyte, a parenchymal cell which makes up to 80% of 
the entire liver mass and performs the majority of the liver functions [1]. The remaining liver mass of ~20% is 
made up of a number of non-parenchymal cells (NPCs) such as; stellate cells (SCs), liver sinusoidal 
endothelial cells (LSECs), biliary epithelial cells (BECs), Kupffer cells (KCs) acting as in situ macrophages, 
and other immune cells, including  lymphocytes and neutrophils [2]. Characterised by its anatomical position 
and intrinsic biochemistry, the liver is involved in the metabolism and clearance of numerous xenobiotics. 
While the metabolic transformation of xenobiotics is usually considered as a detoxification process, some 
compounds which are not toxic may subsequently be converted into toxic substrates in the liver. For example, 
a notable compound that has been intensively investigated in this regard is acetaminophen [3]. The 
pathophysiology, disease course and management of acute liver failure caused by acetaminophen toxicity still 
needs to be fully elucidated, however, acetaminophen hepatotoxicity has been shown via the use of in vitro 
models, to follow a predictable timeline of hepatic failure [4].  
The scientific basis of xenobiotic action and activity is complicated due to the variance in predictability of  
primary and secondary metabolites , as well as variability in individual susceptibility within the population 
[5]. This is true not only for humans but for other species utilised as experimental models. For example, our 
understanding of the mechanisms involved in the occurrence of adverse drug reactions (ADRs) and drug-
induced liver injury (DILI) in humans is also an area that remains limited [6]. ADRs currently represent a 
major encumbrance to the development of new therapeutics with ~21% of drug attrition attributed to toxicity 
during the development process [7]. Despite a wealth of research utilising a variety of model systems in the 
field of xenobiotic safety, our comprehensive understanding of the mechanisms underpinning the impact of 
xenobiotics either on human health or on the environment is not fully established partly owing to the 
complexity of understanding exposure scenarios [8]. As such, the rigorous testing requirements and challenges 
in the global regulatory arena remain, and are apparent in all industries. 
Current in vitro model systems developed to assess hepatotoxicity have a number of limitations including:   
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x Current mainstream 2D models fail to capture the complexities of multicellularity as well as the lack 
of the intricate 3D microenvironment, such as intricate cell-cell and cell-tissue interactions. 
x Primary human liver cell isolation is a complicated procedure that requires well-trained staff and 
established cooperation with the surgical department performing liver resections. However, 
cryopreserved human hepatocytes are available commercially. 
x In vitro models provide limited viability for the study of long-term effects, such as responses to low-
level chronic exposure. Limited availability to all researchers. 
The use of animals in science is a global practice and the main purposes of animal experiments, both in vivo 
and in vitro, are to gain basic biological knowledge for fundamental medical research, to test the toxicity of 
xenobiotics and ultimately contribute towards the discovery and development of novel drugs, and the 
development of vaccines and medical devices [9]. However, due to species-species differences in mechanistic 
responses, it is often difficult to assess results in animal trials and translate these findings to predict the in vivo 
response in humans [10].  In addition to the ethical considerations, there is an increased desire to implement 
the 3R’s (Replacement, Reduction and Refinement) of animal experimentation in research [11-13], which is 
shifting the emphasis on producing more relevant and representative in vitro (human cell and cell line) models 
[14-17]. 
 This review discusses the development of in vitro platforms and expands on the focus of 3D spheroid and co-
culture models and their increasingly integral role in xenobiotic hepatic safety assessment. 
In Vitro Liver Models Utilised for Human Hepatotoxicity Prediction 
The main aim of an in vitro liver model is to be able to capture relevant end points, such as assessing the 
toxicity potential of novel xenobiotics, ADRs or investigating transporter functionality etc. For example, 
simple vesicle models can be used to investigate the uptake and efflux properties of specific transporters [18]. 
This demonstrates that in vitro models do not necessarily have recapitulate the natural in vivo 
microenvironment in order to be utilised successfully for certain end points. However, for certain compounds 
or other endpoints a more complex model that recapitulates in vivo more closely may be necessary.  
Approaches such 3D platforms, co-culture and/or those that incorporate flow parameters such as bioreactor 
technologies may provide better systems.There are a number of in vitro liver models that differ depending on 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
5 
 
their culture conditions and conformations, cell types and other culture parameters. These platforms include 
more classically used primary isolated hepatocytes, hepatic-derived cell lines, and liver slices. More 
conventional cellular models such as simple monolayer cultures are easier to manipulate in the laboratory and 
are much more widely accepted ethically than the use of animal models, but immortalised cell lines and 2D 
hepatocyte cultures maybe less representative of the in vivo liver. Additionally, there is the continually 
developing strand of 3D and co-culture systems including hydrogel and scaffold technologies, and the more 
recently established stem cell-derived hepatocyte-like cells and liver organoids. Another developing area 
within this field is the inclusion of fluid-flow to emulate sheer stress and nutrient exchange seen in vivo as a 
way to improve functionality and in vivo relevance (Fig 1). 
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Figure 1. Schematic of commonly used liver models. There are a multitude of liver models that differ in 
their translational relevance to humans. Systems vary from complex animal models which present significant 
ethical challenges as well as species variation issues, to primary human hepatocytes that, although deemed 
more relevant, suffer from inter-donor variability, rapid de-differentiation in vitro along with sparse 
availability. On the other end of the spectrum are the more conventional cellular models that are easier to 
manipulate in the laboratory and are much more widely accepted ethically but these immortalised cell line 
models are less representative of the in vivo liver. Sandwich cultured hepatocytes retain more in vivo-like 
properties, including polarized excretory function and enhanced morphology and viability of hepatocytes 
compared to monolayer cultures, however these models still lack complex cellular interactions and the 3D 
microenvironment. Cells can be grown in a 2D monolayer setting or the more complex 3D conformation with 
3D set-ups considered to be more representative of the native liver in vivo. The complexity of both 2D and 3D 
models can be increased with the addition of non-parenchymal cells, again producing a more representative 
model via the adoption of a multicellular system, and the addition of flow with some systems incorporating 
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highly complex microfluidic devices. 
Primary Human Hepatocytes (PHH) 
Primary human hepatocytes (PHH) in monolayer cultures are generally still considered the gold standard in 
vitro model for metabolism studies and toxicity investigations [19,20].  When isolated effectively, PHH 
demonstrate a number of favourable characteristics such as phase I and II metabolic enzyme activity, 
expression of liver specific transporters, glucose metabolism, ammonia detoxification, urea secretion and 
albumin production for up to 3 days in culture [21]. However, there are a number of problematic issues with 
this system; (i) loss of liver-specific function/dedifferentiation (PHHs lose their specific-liver function rapidly 
in vitro, including Cytochrome P450 (CYP) expression, and therefore are unsuitable for long-term and repeat-
dose studies) [22,23]; (ii) the isolation procedure of hepatocytes is itself difficult (there is scarce availability of 
tissue and considerable inter-donor variability which can impact on the reproducibility of end point 
measurements) [24]; (iii) classical 2D/monolayer cell culture does not recapitulate the complex 3D in vivo 
microenvironment. PHH in vitro are still widely used despite the difficulties associated with culturing, 
isolating, cost, inter-donor difference, acquisition etc. Much research has therefore been directed towards 
using cryopreserved hepatocytes, hepatic-derived cell lines and other alternatives. 
Research has demonstrated that one way to improve and retain hepatocyte phenotype is to culture cells in a 
3D conformation [25-27]. Mammalian cells in vivo grow in a 3D setting, therefore 2D cell cultures are 
ineffectual at recreating a microenvironment that is representative of this native in vivo configuration [27]. 2D 
cultures also fail to maintain phenotypic characteristics over the duration of the culture period [28]. Other 
strategies to improve PHH function and survival in vitro include the use of growth factors, cytokines and other 
supplementation within the growth media [29]. However, research has shown that one of the most successful 
techniques in retaining hepatocyte function has been their co-culture with other cell types including NPCs [14-
16].   
Since many toxic responses in vivo are mediated by complex interplay amongst a multitude of cell types, the 
predictive capabilities of isolated hepatocytes are limited [30] and therefore, there is a need to establish 
models that integrate NPCs within the culture platform.  Research has shown that intricate hepatocyte-NPC 
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interactions affect the response after exposure to specific compounds. An example of this is vinyl chloride 
monomer (VCM) which is metabolically activated in hepatocytes [31]. This hepatotoxic compound causes 
hepatocellular cancer. However, a long-term effect of VCM is that it gives rise to the formation of a rare 
tumour, haemangiosarcoma (HS) that arises from the LSECs [32]. Furthermore, toxic responses are not only 
mediated by the association of the cells within these multiplexes, but also by the complex 3D interaction 
involving NPCs and the extracellular matrix (ECM) which is believed to be crucial in regulating and 
maintaining hepatic function in vivo [33]. 
The differences between cells grown on flat culture surfaces versus novel 3D formats such as extracted ECM 
attachment surfaces, has been documented since the early 1970’s [34]. With decades of research being 
conducted since then, the compelling similarities of in vivo morphologies and behaviours of cells grown in 3D 
environments have been well demonstrated [35]. Consequently, it is widely agreed that culturing cells in 3D 
provides a much more in vivo-like platform and this format is extensively used in an array of disciplines 
within scientific research such as: cancer medicine/tumour-immune system interactions [36], regenerative 
medicine and tissue fabrication technologies [37], and in the field of toxicology [22].   
There are certainly a number of in vitro pharmacological models that have been developed to assess uptake, 
metabolism and detection of undesired effects, along with a vast number of publications that have addressed a 
number of desirable endpoints. However, only a small fraction of these models will inevitably become 
standardised industrial tools [38]. In part this is due to the specific internal requirements of industries and their 
capacity to incorporate these emerging technologies. Industry screening comprise a battery of models that 
address single end points and in combination make up the tools for xenobiotic safety screening. Even though 
it is widely accepted that 3D cell culture provides a more in vivo-like model, with large sets of historical data 
at their disposal and potential difficulties in comprehensive characterisation and automation of novel 3D 
models, the widespread adoption of these 3D platforms into the already well-established battery of screening 
tools remains a challenge [39].  
Liver Slices  
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There are a number of desirable characteristics attributed to liver slices when compared with other in vitro 
liver models. Unlike primary cell isolations liver slices do not require incubation with proteolytic enzymes 
and therefore cell-cell interactions and other cellular components remain largely undisrupted. The 
maintenance of this microarchitecture provides a more in vivo-like model. Additionally, with many in vitro 
systems, the conditions of isolation vary from species to species; counter to this, a reproducible and repetitive 
procedure is used to prepare and incubate liver slices from different species making this model particularly 
suitable to perform inter-species studies [40].  
Liver slices have been utilised extensively in the field of hepatotoxity and DILI investigations with the main 
advantage of this system being that the liver microarchitecture remains intact with all liver cell types being 
present, along with zone specific CYP450 activity [40]. Human liver tissue can either be obtained from 
removed tissue after surgical procedures such as a partial hepatectomy, or from the non-transplanted donor 
tissue itself [41]. Such liver slices have been utilised as an in vitro method for the prediction of human specific 
toxicity by toxicogenomics investigations. However, human liver slices used from different donors, many of 
whom have underlying conditions, result in the introduction of inter-individual variability. This in turn means 
reproducibility of the investigations can be difficult to achieve [22].  Animal tissue on the other hand, is more 
readily available and can be controlled via perfusion methods using preservation solutions or simple buffers 
[22].  It has been shown that albumin production and phase II enzyme expression remain relatively stable for a 
period of up to 96 hours of culture, with the studies typically lasting between 30 minutes and 5 days using rat 
liver slices [42-44]. The main limitation with using freshly cut liver slices is their longevity, meaning that 
repeat-dose studies cannot be achieved with this model beyond three days. Inter-individual variability is also 
seen in liver slices taken from different rats within a strain [45,46].  
It is well known that the long-term conservation of metabolic competence for in vitro models is difficult to 
achieve but it has been reported that metabolic capacity is better preserved in human liver slices when 
compared to PHH [41,47]. However, conflicting reports have demonstrated that xenobiotic metabolism in 
liver slices is impaired after 24 h of culture [48]. Research has demonstrated good in vitro to in vivo 
correlations for the qualitative metabolism of xenobiotics in liver slices obtained from multiple species, 
however, the use of liver slices may be limited to identifying low- and high-clearance compounds [40].  
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Despite their short-term viability, liver slices have been used extensively over the years to investigate 
metabolism and toxicity of a number of xenobiotics. Olinga et al. showed that in human liver slices, all 
hepatocytes within the slice had an equal rate of metabolism of lidocaine [47]. Elferink et al. [49] further 
evaluated the utility of human liver slices as an in vitro platform for the prediction of human-specific toxicity 
by toxicogenomics. They found that human liver slices retained a relatively stable expression of transporters 
and enzymes that are involved in drug metabolism during the 24 hour culture period.  
Liver slices have also been used in conjunction with bioreactor platforms such as the multiwell plate platform 
engineered by CNBIO [50]. This combined approach has been utilised as a means of increasing the 
complexity and representativeness of the liver slice platform as fluid shear stress has been shown to improve 
liver-specific functional output [51]. Liver slices are placed into the multiwell chambers of the plate and 
media flow controlled by a pneumatic underlay. The bioreactor is produced from polystyrene and has two 
connected chambers, one for the media reservoir, and the second is the reactor chamber. This reactor chamber 
can be used for culturing liver slices (and for the culture of isolated hepatocytes) with polycarbonate scaffolds 
[52]. This engineered platform enables the cells or liver slices to be cultured in an environment close to that of 
the in vivo liver. The system incorporates media flow, oxygen gradients and shear stresses. The experimental 
set up is able to recapitulate oxygen gradients similar to that seen within the liver sinusoid (145 µM to 50 µM 
at a flow rate of 0.25 mL/minute) [52]. Hepatocytes cultured using this system have improved longevity when 
compared with conventional monolayer cultures. However, liver slices utilised in this platform are still not 
able to provide a model for repeat-dose toxicity studies due to their short term culture longevity.  
Hepatic-derived Cell Lines  
To overcome some of the previously mentioned limitations with PHH, immortalized hematoma-
derived/hepatocellular carcinoma-derived cell lines have been utilized extensively. Cell lines previously used 
in toxicological investigations include; HepG2, C3A, HepaRG, Huh7 [53-56]. These cell lines inherently 
overcome the downfall of inter-individual differences of primary isolated hepatocytes [57], and are 
characterised by having a relatively stable phenotype, ease of manipulation in the laboratory along with 
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unlimited life span [53]. The main limitation with utilising these cell lines is that they generally possess 
reduced metabolic competence due to lack of expression of key metabolising enzymes [58]. 
Extensive work has been carried out with the HepG2 cell line with regards to toxicological and 
pharmacological assessment, and this cell line was first generated in the 1970’s [42]. These cells possess a 
number of attractive characteristics such as: (i) nuclear transcription factor (Nrf2) expression, which is 
essential for drug metabolism and toxicity response [59]; (ii) unlimited growth and availability and the 
absence of inter-donor variability ensuring reproducible results [60];  and (iii) it is an easy-to handle cell line 
with uncomplicated culture protocols [61]. Research has targeted the development of classical monolayer 
formats to more complex 3D models including spheroids, with HepG2 spheroids showing markedly different 
gene expression when compared to monolayer cultures [62]. Chang and Hughes [62] revealed that 
significantly more genes related to ECM, cytoskeleton, and cell adhesion were expressed in monolayer cells, 
whilst genes involved in liver-specific functions of xenobiotic and lipid metabolism were upregulated in 
HepG2 spheroids. In addition, more genes involved in cell cycle and regulation of growth and proliferation 
were upregulated in monolayers (Table 1). For example, CYP1A1 and ALB (albumin) expression was ~ 10.5 
fold and 2 fold higher respectively in 3D spheroid cultures when compared with monolayers, whilst COL1A1 
(alpha 1 type-1 collagen) and GSPG2 (versican) expression was ~ 70 fold and 11 fold higher respectively in 
monolayer cultures when compared with 3D spheroids. 
Table 1 – Number of genes upregulated by at least 2 fold in HepG2 monolayers or spheroid as determined by 
microarray analysis [62]. 
 Number of Genes Number of Genes 
Category Monolayer Spheroids 
Total 250 210 
Extracellular Matrix 10 0 
Cytoskeleton 10 5 
Cell Adhesion 21 4 
Cell Cycle 13 7 
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Growth/Proliferation 25 10 
Xenobiotic Metabolism 0 6 
Lipid Metabolism 4 11 
Apoptosis/Cell Death 11 12 
Signal Transduction 26 20 
Transcription 20 21 
It has been demonstrated that with the lack of appropriate levels of CYP expression when compared to PHH, 
HepG2 cells do not fully represent the phenotype of the in vivo hepatocytes and therefore that the detection of 
many hepatotoxic compounds utilising the HepG2 cells line is inaccurate, and for non-liver specific toxins this 
model is ineffectual [63]. It is however still the case that 2D cultures of hepatic-derived cell lines are valuable 
in the early stages of safety assessments [22] and liver cell lines can still provide a convenient and pragmatic 
initial tool for early screening and drug safety assessment [64].   
C3A cells are a sub-clone of the HepG2 cell line that demonstrate more advantageous characteristics 
compared with the parent cells. C3A cells are selected for their contact-inhibited growth characteristics, 
upregulated albumin production and alpha fetoprotein production alongside their ability to proliferate and 
thrive in glucose-deficient media [65]. These characteristics have made C3A cells a more representative 
model for hepatotoxicity studies with a number of researchers utilising this cell type with the more complex 
3D culture systems [57].  
The HepaRG cell line is another hepatocellular carcinoma-derived cell line that has been of interest over the 
last decade [66]. It is a human cell line that exhibits a number of attractive qualities and unique features when 
compared to the more commonly used HepG2 cells [55]. HepaRG cells have been shown to express a number 
of phase II enzymes and membrane transporters comparable to freshly isolated or cultured primary human 
hepatocytes [58,61,67]. HepaRG cells, when seeded at low density, acquire an elongated undifferentiated 
morphology. They then actively divide and after having reached confluency, form typical hepatocyte-like 
colonies surrounded by biliary epithelial-like cells [55]. In addition, much of the literature has reported 
enhanced CYP450 expression along with improved liver-specific functionality [22,55,58,66].  
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
13 
 
Guillouzo et al. [55] demonstrated that the HepaRG cell line was more sensitive to metabolism-mediated 
toxicity when compared with HepG2 cells. They found that HepaRG cells expressed various CYPs (1A2, 
2B6, 2C9, 2E1, 3A4) and the nuclear receptors, constitutive androstane receptor (CAR) and pregnane X 
receptor (PXR) at levels comparable to those found in cultured PHH, and much improved when compared to 
the expression levels in HepG2 cells. HepaRG cells also expressed phase II enzymes, apical and canalicular 
ABC transporters and basolateral solute carrier transporters, albumin, haptoglobin as well as aldolase B which 
is a specific marker of adult hepatocytes. The findings of Guillouzo et al. [55], demonstrate that HepaRG cells 
models have the potential to replace PHH models for xenobiotic metabolism and toxicity studies. McGill et al. 
[68] concluded that HepaRG cells are a useful model to study mechanisms of acetaminophen (APAP) 
hepatotoxicity in humans. They found that HepaRG cells that were exposed to APAP at varying 
concentrations resulted in glutathione depletion, APAP-protein adduct formation, mitochondrial oxidative 
stress, peroxynitrite formation, mitochondrial dysfunction, and lactate dehydrogenase (LDH) release. This 
analysis indicated that these key mechanistic propagators of APAP-induced cell death were the same as in the 
in vitro rodent models and primary cultured mouse hepatocytes [68].  
Gerets et al. [58] carried out a comprehensive assessment of the HepaRG cell line, investigating mRNA levels 
and CYP activity in response to a number of inducers. This study characterised PHH, HepG2 and the novel 
HepaRG cell lines in direct comparison with each other. All of the cells in this investigation were cultured in a 
monolayer multiwell format and were compared with regard to their metabolism and potential to detect 
hepatotoxicity. Gerets et al. [58] concluded that HepG2 cells in this 2D environment responded weakly to the 
different inducers (beta-napthoflavone/BNF, phenobarbital/PB and rifampicin/RIF), when compared with 
PHH and the HepaRG cells at the gene expression and CYP activity levels, whilst HepaRG cells appeared to 
be most suitable for these induction studies. However, HepaRG cells were not as predictive for hepatotoxicity 
as PHH and were more comparable to HepG2 cells. 
One of the main limitations with the HepaRG cell line as a model for hepatotoxicity investigations is the long 
culture procedure that is required. Cells are seeded at low densities and after a period of 14 days, cells are able 
to differentiate into 2 cell types. This pre-differentiation culture phase incurs cost and also time when 
compared to more commonly used cell lines such as HepG2/C3A cells. Specialist culture media and 
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supplements are required for the entirety of the culture procedure and, licensing is required to culture the cells 
meaning the cost of culturing the HepaRG cells can be as much as 100 times more expensive than the more 
commonly used cell lines. As a research tool this means that availability to all researchers is limited. 
However, terminally differentiated, commercially available cryopreserved HepaRG cells can be obtained with 
these cells exhibiting many of the characteristics of PHH including similar cellular morphology, the 
expression of key metabolic enzymes, and the expression of nuclear receptors. Dissimilar to other hepatic-
derived cell lines such as HepG2/C3A, these cryopreserved HepaRG cells have high cytochrome P450 activity 
and complete expression of all nuclear receptors [69].  
Co-cultures 
It has been demonstrated that culturing hepatocytes with other cell types increases their longevity and 
functionality [70]. The culturing of hepatocytes with NPCs has been investigated since the late 1970’s [71] 
and is still being intensively researched. The predictive capabilities of isolated hepatocytes can be limited 
[30]. Therefore, in order to represent the multicellularity of the liver, culturing isolated hepatocytes with NPCs 
is an important facet for in vitro cellular models [38]. Much of the research to date has demonstrated that 
culturing primary isolated hepatocytes, with NPCs not only increases liver-specific functionality, but also 
improves the longevity of the cultures [15-17]. Whilst there is a wealth of research in co-culture models, the 
emphasis has shifted to producing 3D co-cultures, where not only multiple cell types can interact but they can 
grow in a physiologically relevant manner [38]. Figure 2 shows that there are varying selection of the methods 
for producing co-culture models of hepatocytes and incorporating multiple NPCs within the model. 
Research has shown that hepatocyte function and stability is improved regardless of whether the secondary 
cells used are primary or not. Bhandari et al. [14] showed that when culturing PRH with murine 3T3 
fibroblasts, there was a reciprocal relationship whereby the cellular interactions in the co-cultures ensured 
survival, and increased stability and function of both cell types. Thomas et al. [16] further expanded on the 
previous work by Bhandari et al. [14] and described a co-culture model where activated rat SCs were cultured 
with isolated PRH in a spheroid model. This co-culture spheroid model demonstrated the development of bile 
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canaliculi-like structures, complex ECM within the spheroid and, when compared with monoculture 
spheroids, superior cytochrome P450 functionality [16].  
Peters et al. [72] were able to demonstrate that PRH co-cultured with rat liver epithelial cells displayed higher 
levels of albumin secretion and the longevity of CYP enzyme activity was enhanced when compared to 
conventional PRH monolayer cultures. It was concluded that this co-culture model was the most applicable 
method for investigating cytokine-mediated induction of acute-phase proteins, due to there being a three-fold 
increase in fibrinogen secretion in comparison with the conventional monolayer cultures.   
Kang et al. [73] produced a model system whereby PRH and LSECs were cultured on the opposite sides of a 
transwell membrane, allowing prolonged viability for a period of up to 39 days, as well as the stable presence 
of hepatocyte-specific differentiation markers. Dedifferentiation of primary hepatocytes is a commonly 
discussed limitation of classical in vitro liver platforms. However, the model system developed by Kang et al. 
[73] demonstrated that PRH can maintain this differentiated status for an extended period as verified by the 
mRNA expression of albumin, transferrin, and hepatocyte nuclear factor 4.   
KCs have been the focus of much research and it is accepted that this NPC plays a role in the development of 
DILI. Jemnitz et al. [74] produced a 2D co-culture model of PRH and KCs and concluded that the hepatocyte-
KC co-culture model provided a good platform for the prediction of chemical hepatotoxic potential. KCs have 
also been shown to detect hepatocyte stress and damage from model hepatotoxins in vitro, leading to the 
release of cytokines [75]. Hepatocytes culture in isolation would not be able to capture this release of 
inflammatory response further strengthening the view that co-culture and, in particular, co-culture with KCs 
may increase the sensitivity of in vitro liver models to DILI and specific hepatotoxins [75].  
BECs line the biliary tracts and are often targets of liver disease such as cholestatic liver disease and because 
of this, BECs have been the subject of much NPC research [22]. Auth et al. [76] developed a model where 
hepatocytes were co-cultured with BECs and demonstrated substantially increased protein synthesis and urea 
production. Hepatocytes in isolation exhibited low levels of CYP450 activity; however, in co-culture with 
BECs, CYP450 activity remained stable for up to 3 weeks. Auth et al. [76] concluded that co-culture of 
human hepatocytes with BECs restored the synthetic and metabolic liver function in vitro.  
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Figure 2. Schematic of a selection of in vitro co-culture liver models. (A) shows hepatocyte cultures that 
have been grown on a collagen coated surface and then overlaid with NPCs. (B) demonstrates the much-
utilised sandwich culture method whereby hepatocytes are cultured between two layers of collagen and then 
subsequently overlaid with NPCs. (C) demonstrates the structural formation of hepatocyte spheroids including 
NPCs. In this conformation there are multiple and direct cell-cell contacts between the parenchymal cells and 
the NPCs. There are a number of methods for culturing hepatocyte spheroids, however it is becoming more 
common to utilise certain low-attachment surfaces. (D) in this sandwich culture the NPCs are in direct contact 
with the hepatocytes and then subsequently sandwiched between two layers of collagen matrix. 
 
3D Liver Microtissues 
Spheroids 
3D cultures of hepatocytes and hepatic-derived cell lines is a rapidly developing field, whereby researchers 
and bioengineers endeavour to capture the complexity of the microenvironment with a view to improving the 
liver-specific functionality, longevity and relevance of the cultured cells [42]. The recent progress in 3D in 
vitro liver spheroid models may improve the ability to predict hepatotoxicity of novel compounds, in part 
owing to the better recapitulation of the native physiology of the liver [77]. It has been shown that the re-
establishment of cellular polarisation is critical in maintaining gene expression and hepatocyte-specific 
function [78]. With 2D cultures of hepatocytes unable to model the multiple apical and basolateral membranes 
of the in vivo hepatocytes, it is crucial that models are capable of restoring this highly-complex 
microenvironment. There are now a number of 3D liver approaches which help restore this highly-complex 
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microenvironment including hydrogel [12,37,79,80] and scaffold based technologies [81], as well as the 
production of “hepatospheres” or liver spheroids [82].  For the latter, techniques to produce spheroids have 
become progressively more refined and accessible and they are being increasingly utilised to assess areas such 
as xenobiotic penetration, metabolism and hepatotoxicity [83]. 
The basic underlying principle for the production of spheroids is that monodispersed cells (isolated cells from 
fresh tissue or cell lines) are capable of reforming a 3D configuration via self-reaggregation if adhesion to the 
substrate they are being cultured in is prevented [84]. According to the prevalent theory of self-assembly, in 
the absence of external influences, cells will self-organize into a spherical conformation as a result of specific 
local interactions amongst the cells themselves [79]. In conjunction with this, the differential adhesion 
hypothesis (DAH) states that tissues are treated as liquids composed of mobile cells whose varying degrees of 
surface adhesion causes them to reorganize spontaneously in order to minimize their free energy [85]. Thus, 
cells will migrate to be near other cells of comparable adhesive capacity in order to maximize the strength of 
the bonds between them. This in turn produces a more thermodynamically stable structure [79].   
 One of the main advantages of culturing cells in a spheroid is the increased cell-cell interactions and cell-
ECM interactions when compared to 2D monolayer culture [27]. The majority of cells are in close contact 
with each other and are able to communicate and produce their own ECM. Cells within a spheroid have 
virtually 100% of their surfaces in contact with neighbouring cells unlike a 2D monolayer. On this basis, cells 
in a spheroid conformation mimic much more closely the cells natural in vivo-like state, with figure 3 
illustrating the differences between monolayer cells and cells grown in a 3D spheroid model.   
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Figure 3. Comparison of monolayer cells and cell cultured in a spheroid. (A) Monolayer cells become 
flattened, have very few cell-cell contacts, unlimited access to the media as well as ease of waste product 
expulsion into the media. (B) Proliferative cell lines grown within the spheroid have numerous cell-cell 
contacts, do not become flattened and retain an in vivo-like morphology. Cells on the periphery of the 
spheroid proliferate and have greater access to media and can remove waste products to the media easier than 
those cells situated in the centre of the spheroid. These cells have less access to the nutrients within the media, 
less access to oxygen due to an oxygen diffusion gradient. Waste products may also accumulate in this central, 
and potentially this may cause necrotic regions. Over the duration of the culture period, the size of these 
spheroid can increase dramatically. (C) Non-proliferative cells such as PHH/PRH grown within a spheroid 
again have numerous cell-cell contacts and retain an in vivo-like morphology. Similar nutrient and solute 
gradients form within the spheroids. However, as there is no proliferative rim, the overall size of the spheroid 
remains relatively constant over time, reducing the formation of necrotic areas due to hypoxia.   
A number of hepatic-derived cell lines are used in classic 2D culture including; C3A, HepG2, HepaRG and 
Huh7 [27,57,86,87] are capable of forming 3D liver spheroids and such models are most commonly being 
used in the early stages of assessing xenobiotic safety [22]. HepG2 cells cultured as a spheroid model show 
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the morphological characteristics of hepatocyte-like cells as well as the formation of bile canalicular-like 
structures. These HepG2 spheroids also exhibit a highly compact structure with tight cell-cell interactions 
[88].  Studies such as those from Li et al. [27] and Ramaiahgari et al. [12] have assessed a number of key 
functional outputs including; (i) cellular interactions as shown by E-cadherin, electron microscopy, β1-
integrin and β-catenin which are indicative of polarity; (ii) epithelial characteristics (CK7/8); and (iii) 
proliferative capabilities (Ki-67). Wrezesinski et al. [54] along with others [12,57] have also investigated end 
points such as albumin and urea production, and metabolic competence via CYP activity (CYP1A1, CYP1A2, 
CYP3A4, & CYP7A1). These studies have conclusively elucidated that spheroids, and perhaps in general, 3D 
cultures of the HepG2 cell line show enhanced liver-like functionality when compared to the more traditional 
2D cultures. However, it is widely accepted that with their low metabolic competence [22], HepG2 spheroids 
are limited in their use as a model for toxicological investigations and may underestimate the toxicity potential 
of compounds [61].  
The formation of bile canalicular-like structures within  HepG2 spheroids has been increasingly investigated 
in recent years [12,89]. Much of the work has shown the formation of these structures but further investigation 
into whether or not they are functional in producing bile salts and their subsequent transport is required [22]. It 
has been shown in work previously undertaken with the HepG2 and C3A cell lines [27,88,89], that there are 
several quantifiably useful end points such as albumin, urea secretion and ATP content that can be used to 
confirm in vitro 3D liver model phenotype. Recently Gaskell et al. [57] demonstrated secondary structure 
functionality in C3A spheroids via the transport of CMFDA by the canalicular transporter MRP2. This line of 
investigation has yet to be fully characterised in primary hepatocyte spheroids and would help strengthen the 
case that 3D spheroid cultures may be better placed to assess hepatobiliary transporter-based compounds. 
Nevertheless, HepG2 or C3A cells have poor metabolic competencies when compared with PHH in 2D and 
this is one of the main limitations with these commonly used cell lines [60]. 
There are a limited number of publications using HepaRG cells in a 3D liver microtissue model [22]. 
However, with the accumulation of studies detailing more comparable functionality to that of PHH 
[55,58,66,90] and improved functionality when compared with the more commonly used cell lines such as 
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HepG2 and C3A cells in 2D culture, it is anticipated that a 3D HepaRG model may bridge the gap between 
conventional monolayer cultures and in vivo physiology. 
Gunness et al. [91] reported that they were able to produce 3D organotypic cultures of the HepaRG cell line 
using the high-throughput hanging drop method. They were able to maintain the cultures for 3 weeks and 
showed conservation of high liver-specific function for the duration of culture via phase 1 enzyme (CYP3A4, 
CYP2E1) and transporter activity (MRP2), expression of liver-specific proteins (albumin, urea) and response 
to a number of drugs (acetaminophen, troglitazone and rosiglitazone). In order to assess whether the 3D 
HepaRG cultures were a more appropriate model to study drug toxicity, 2D HepaRG cultures were set up in 
parallel with the 3D cultures over 3 weeks. 3D HepaRG cultures showed higher sensitivity for acetaminophen 
and troglitazone toxicity, and the 3D cultures maintained high levels of liver-specific functionality, including 
phase I enzyme and transporter activity,  and also production of liver-specific proteins including albumin and 
urea. These investigators [91] therefore suggested that these 3D organotypic HepaRG cultures, formed via the 
hanging drop technique, provide a suitable in vitro tool for assessment of drug-induced hepatotoxicity.  
HepaRG cells when cultured differentiate into hepatocyte-like cells and biliary-like cells and it has been 
demonstrated that bile canalicular-like structures form throughout 3D models [92]. The fact that the HepaRG 
cell line differentiates into two distinguishable cell types, means that the resultant cultures are intrinsically co-
cultures in nature. Compared with the more commonly used hepatic-derived cell lines, HepaRG cells possess 
many more advantages with regards to specific functional output, formation of secondary structures, 
upregulated metabolic capacity etc. and this makes them much more comparable to PHH [58,67,93]. 
The main advantage of 3D models, and in particular the spheroid model, is that very few cells are required to 
produce a functional spheroid [22]. For example, we have been able to demonstrate that a functional primary 
rat hepatocyte (PRH) spheroid can be produced from as little as 2000 cells/well on a 96-well, liquid-overlay 
plate.  
PRH spheroid models are well characterised and have been used since the 1980’s [26]. These spheroids have 
been shown to have a smooth outer surface with numerous pore-like openings leading to secondary structures 
shown to be similar to bile canaliculi [25]. As well as the formation of these bile canalicular-like structures, 
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cells within the spheroid have shown polarisation as assessed by staining of apical HA4 and basolateral 
HA321 membrane bounds proteins [25], and dipeptidyl peptidase 4 (DPP IV) by immunohistochemical 
staining as an apical membrane marker demonstrated by Wang et al. [94]. Much of the initial work was 
carried out on characterising the cellular morphology and polarity in conjunction with the formation of bile 
canaliculi [25,95]. However, more recent work has involved examining intra-cellular interactions and 
communication [89] along with oxygen concentration and gradients throughout the spheroids [96,97].  
Due to metabolism and uptake of numerous solutes by hepatocytes, the composition of blood changes as it 
flows along the sinusoids from the periportal zone to perivenous zone. Concentration gradients of substrates, 
products, and hormones are formed as a result and these gradients are considered to be drivers of liver 
zonation [98]. This sinusoidal zonation is extremely important to discuss when looking at hepatotoxic 
potential of xenobiotics. If we look at APAP toxicity for example, glucuronidation, the dominant pathway of 
conjugation at high APAP concentrations (>5mM), has been shown to be more rapid in perivenous cells than 
in periportal cells. Prolonged exposure to high concentrations of APAP damages perivenous cells expressing 
higher levels of CYP2E1 than periportal cells [99]. This demonstrates that perivenous hepatocytes exhibit 
increased APAP vulnerability and extensive glutathione depletion when compared with periportal cells, and 
emphasises the importance of being able to recapitulate liver-specific zonation and solute gradients in vitro. 
As one of the circulating signals, oxygen plays an important role in modulating zonation along the liver 
sinusoid. Its partial pressure is about 60 to 65 mm Hg (84-91 μmol/L) in the periportal blood and falls to about 
30 to 35 mm Hg (42-49 μmol/L) in the perivenous blood [100,101]. Research utilising liver spheroids has 
become progressively more interested in the physiological oxygen tension along the sinusoid, with increasing 
focus on trying to experimentally recapitulate oxygen profiles within 3D liver models.  
Oxygen demand and concentration throughout the in vitro spheroid models remains an interesting point of 
research because, it is desirable that all the cells are viable and free from necrosis. Much of the literature 
describes that spheroids with a diameter >150µm form a necrotic core due to hypoxia and lack of nutrients 
[102]. For an in vitro model used in cancer medicine for example, necrosis is a desirable characteristic 
because; larger tumour spheroids are characterised by an external proliferating rim, an internal quiescent zone, 
and a necrotic core resembling the cellular heterogeneity of solid in vivo tumours [103]. However, for a model 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
22 
 
that attempts to recapitulate the in vivo-like liver microenvironment, this is an undesirable characteristic. 
Being able to determine the oxygen diffusion and consumption within spheroids, and using this information to 
try to mimic the oxygen profile seen within the  liver sinusoid, would provide a more accomplished model 
than classic monolayer culture, and a more comparable one to that of the liver in vivo. In the field of 3D 
tumour cell culture, much research has been dedicated to the quantitative description of tumour vascular 
networks whilst the consideration of oxygen consumption is largely neglected. Whilst oxidative respiration in 
standard 2D cell culture has been widely studied, this aspect of characterisation has also been lacking with 3D 
in vitro liver models [104].  
Sakai et al. [89] demonstrated that PRH cultured as spherical multicellular aggregates provided a more useful 
model than the traditional monolayer culture. It was shown that PRH rapidly lost expression of a number of 
liver-specific genes when cultured in monolayer from day 1 up to day 5 (determined by quantitative PCR). In 
direct comparison, the PRH spheroid cultures conferred higher levels of expression of these liver-specific 
genes when compared to the monolayer cultures, for a period of up to 10 days. These results suggested that 
PRH cultured as spheroids acquire intercellular organisation that may permit maintenance of metabolic 
competence [82,89].   
As outlined previously, PHH are still considered by many to be the gold standard as an in vitro tool for DILI 
and toxicity investigations [20]. Despite the number of limitations with primary cells, spheroid systems can be 
produced from a low cell number, so a large number of spheroids can be produced from a small fraction of a 
single isolation suspension [22]. It is also important to reiterate that hepatocytes isolated from different donors 
display marked variations in gene expression levels, and thus may respond differently in hepatoxicity 
investigations. 3D spheroid culture, however, enables the production of spheroids utilising cells from a single 
donor or pooled hepatocytes. The advantage of utilising pooled hepatocytes is that the resultant spheroids may 
better predict average population drug responses and conversely, spheroids produced from single donors 
allows for more direct in vivo variability comparisons [105].  
Messner et al. [106] were able to characterise a multi-cell type spheroid system incorporating PHH and liver-
derived NPCs. This subsequent system was shown to be functional for a period of up to 5 weeks, 
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demonstrating that longevity of the cultures is vastly improved compared with the conventional monolayer or 
sandwich cultures of PHH. Secondary structure formation was confirmed in these spheroids via 
immunohistochemical staining for the apical transporters MDR1 and BSEP, demonstrating functional 
polarisation of hepatocytes within the spheroids. Messner et al [106], were able to demonstrate that the PHH 
spheroid model incorporating NPCs has improved longevity in culture, stable albumin production over the 
duration of culture period with KCs showing responsiveness to inflammatory stimuli. In these investigations, 
Messner et al. [106] were able to incorporate both the 3D microenvironment and multiple cell types within a 
single model, producing a more representative in vitro tool for the assessment of DILI. These 3D, 
multicellular models show promise for drug discovery investigations as the much improved longevity and 
viability of the cells will enable the assessment of long-term effects of compounds over repeat-dose scenarios, 
an area initially highlighted as a limitation of many of the commercially available in vitro liver models.  
A more recent study carried out by Bell et al. [107] produced PHH spheroids using ultra-low attachment 
plates. Spheroids in this instance were cultured for a period of up to 5 weeks in serum-free culture medium. 
Spheroid size decreased over time alongside increasing expression of E-cadherin, suggesting that the cells 
within the spheroid model are becoming more tightly incorporated via spheroid compaction [108]. MRP2 
staining revealed the formation of bile canaliculi-like structures throughout the spheroid body over the 35 day 
culture period, indicative of stable functional polarisation of hepatocytes [22].  A direct comparison can 
subsequently be made between the multi-cell spheroids produced by Messner et al. and the monoculture 
spheroids by Bell et al. Interestingly both researchers demonstrate improved longevity of up to 5 weeks in 
culture compared to conventional models via stable albumin production over the duration of the culture 
period. This demonstrates that co-cultures of NPCs and PHH within this spheroid model may not be essential 
for improving the longevity. However, the co-culture spheroid models with the inclusion of KC place 
themselves well to investigate immune mediated toxicities whereas a monoculture hepatocyte spheroid model 
may be inadequate for capturing this specific end point analysis.  Both models demonstrate preserved hepatic 
phenotypes and long-term functionality for the investigations into chronic toxicity assays and repeat-dose 
studies. 
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There are a number of techniques that have been implemented for the production of PHH and PRH spheroids 
including, spinner vessels and orbitally shaken flasks [109].  However, limitations of these systems include 
the inability to control spheroid size, difficulties with manipulation in the lab as well as these systems 
requiring relatively high cell numbers. Scaffold-free systems that allow the formation of size controllable 
primary cell spheroids has currently only been performed using a hanging-drop system as described by a 
Kelm and Fusseneger [110] and the use of ultra-low attachment (ULA) plates described by Bell et al [107].   
Sufficient supply of oxygen to the cells is crucial for a functional 3D in vitro model trying to recapitulate the 
liver microenvironment. Primary hepatocytes have a relatively high metabolic activity compared with their 
hepatic cell-line counterparts, and thus, primary hepatocytes have a high oxygen turnover which can be up to 
ten times greater than other types of non-proliferative cells [111]. Increased levels of albumin and urea 
production, along with other liver-specific functions have been seen to correlate with higher oxygen uptake 
rates (OUR) of hepatocytes [111]. The idea that increased functional output increases the oxygen demand on 
the cells suggests that even the basic set up of in vitro liver models needs to be accurately determined to allow 
sufficient oxygen to diffuse through the media and into the cells. It also outdates the idea that spheroid 
diameter is the most crucial factor in determining the formation of central necrosis. It is much more likely that 
the combination of specific cellular OUR, along with their proliferative characteristics and the experimental 
set up are equally as important.  
Scaffold and Hydrogel Technology 
Spheroids can be produced by embedding hepatocytes into non-adhesive hydrogels [112]. Spheroids form via 
the process of cellular self-assembly [79], and the cells that self-assemble into spheroids have been shown to 
achieve increased gene expression and retention of the native cell phenotype when compared to 2D cultures 
[110]. Even though spheroids have been shown to form without scaffolds and hydrogels, not all cell lines are 
able to form spheroids via self-aggregation [113] and thus, the 3D microtissue system required is heavily 
dependent on the cell type being utilised.   
Lee et al. [87] were able to produce functional encapsulated spheroids using Huh7 cells. These encapsulated 
spheroids were functional for a period of up to 3 weeks and the microenvironment in which they were 
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cultured could be adapted depending on the stiffness of the hydrogels. In this case, an in vitro model 
representative of normal liver could be generated by utilising low stiffness hydrogels, and cirrhotic liver by 
increasing the stiffness of the gels. Lee et al. also demonstrated that spheroids cultured within the low stiffness 
hydrogels had the highest rates of proliferation, albumin secretion and CYP450 expression over the culture 
time.  
Another way in which hepatocytes can be cultured to mimic the 3D microenvironment is the use of scaffolds 
produced from either natural or synthetic material [22]. Natural scaffold systems are thought to allow for 
biocompatibility with the cells, with the scaffold itself mimicking the native ECM and conferring multiple 
cell-ECM interactions. However, these naturally liver-derived scaffolds are inherently variable leading to 
difficulties with reproducibility of experimental data. Decellularised human livers are considered the ideal 
ECM alternative because both the 3D microarchitecture and biological features of the native liver are 
preserved. However, human donor livers are in short supply as decellularised scaffolds, and the intrinsic inter-
donor differences means that reproducibility of experiments can be difficult [114]. This limitation can be 
overcome with the use of synthetic scaffold systems and, similarly to hydrogels, they can be purposely 
engineered to allow for specific 3D conformations and cell-specific scaffolds [115,116]. Hepatocytes have 
been shown to have an affinity for galactose residues such that scaffold systems presenting galactose on their 
surfaces allows for improved hepatocyte adhesion, leading to an improved functional system [117,118].  
An example of synthetic scaffolds that has been increasingly used within the field of 3D cell culture is the 
Alvetex® (Reinnervate), which has been produced from cross-linked polystyrene. This system has been 
shown to be biocompatible and the manufacturing of the scaffold has shown little batch-to-batch variation 
allowing for more reproducible experimental data [119]. The scaffold is engineered into thin (200 µm) 
membranes that are able to fit into conventional multiwell plate plasticware. Knight et al. [119] reported that 
cells seeded on to the scaffold system are able to form close cell-cell interactions and cellular differentiation, 
allowing the formation of thin tissue-like cultures. Furthermore, the HepG2 cell line has been shown to have 
improved liver-specific functionality when cultured with the Alvetex® scaffold including higher viability over 
the culture period and the formation of bile canaliculi within the tissue-like cultures [120]. Rat hepatocytes 
have also been cultured using the Alvetex® scaffold system and have been shown to retain their native 
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cuboidal morphology along with much improved viability when compared with conventional monolayer 
cultures. These 3D cultures display gene expression associated with phase I, II and III drug metabolism under 
basal conditions along with increased sensitivity to acetaminophen toxicity [121].  
One on the main limitations with the hydrogel technologies is that there is poor mass transfer of nutrients, 
oxygen and xenobiotics and cell retrieval is more difficult [22]. Cell retrieval difficulties have been previously 
described by Godoy et al. [22], developing the idea that downstream analysis becomes much more 
challenging with reduced cell numbers. This potentially remains a major caveat of hydrogel systems,  as 
altering the hydrogel stiffness may impact the ability to dissociate cells from the gels themselves. However, 
with the development of more simplistic methods, the utilisation of non-adhesive hydrogels reduces cell-
substrate interactions, thereby increasing the important cell-cell interactions which are vital for retaining 
functionality as well as the driving process of self-assemble [79]. One of the main advantages of using non-
adhesive hydrogels for the production of 3D microtissues is that hundreds of spheroids can be produced with a 
single pipetting step. This in turn means that the hydrogel method may lend itself to long-term, repeat-dose 
toxicological investigations [79].  
In recent years it has been shown that the cellular microenvironment contributes to the spatially and 
temporally intricate signalling domain that directs cell phenotype, and thus the idea that cellular scaffolds 
serve simply as a vehicle with which to assess the expression of specific genes and subsequent functionality 
has become outdated [37]. Tibbitt et al. [37] concluded that a cell can no longer be thought of as a single 
entity defined by its genomic material, but must also be regarded in the context of the ECM, soluble growth 
factors, hormones, and other molecules that regulate organ formation and function. It is better understood that 
the extracellular microenvironment coordinates intracellular signalling cascades that influences phenotype by 
altering gene and subsequent protein expression [122,123].  
Liver organoids 
Organoids are 3D culture models in which adult stem cells and their progeny grow and are able to recapitulate 
the natural physiology of the cells in vivo. Organoids have been successfully derived from a number of organ 
systems for both animals and humans [124]. “Organoid” is a term that, in the past, was used interchangeable 
for in vitro spheroid models. However, the term organoid refers to “stem cell derived” self-organising 
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organoids [125].  Organoids can be produced from two types of stem cells which include pluripotent stem 
cells (PSCs) such as embryonic stem cells (ESCs) or induced pluripotent stem cells (iPSCs), and organ-
specific adult stem cells (ASCs) such as hepatic progenitor cells (HPCs), which are tissue-specific resident 
stem cells. Organoid systems have the potential to aid in the development of personalised medicine/treatment 
strategies and have previously been utilised to investigate a number of disease models [125,126].  As with 
hepatic-derived cell lines, 2D culture of PSCs is relatively amenable within the laboratory. However, long-
term culture of PSCs with maintenance of stem cell characteristics is a limiting factor [127]. Additionally, 2D 
cultures fail to produce in vivo cell polarisation and intricate cellular interactions, and cannot recapitulate the 
complex 3D microenvironment as seen in vivo [35]. As with hepatic-derived cell lines and primary isolated 
cells, 3D culture of PSCs has become a rapidly developing field in order to overcome the limitations of 
monolayer culture. Huch et al. [128,129] developed a 3D culture system of HPCs which demonstrated long-
term genetically stable expansion (>1 year). The organoid models were derived from both Lgr5+ cells 
(mouse) and EpCAM+ (normal human liver) ductal cells. It was shown that the original phenotypic epithelial 
architecture of the cells were maintained and that organoids were differentiated in vitro toward hepatocyte-
like and cholangiocytes-like cells [125].  Additionally, upon transplantation of the Lgr5+ organoid into 
impaired mouse livers, this propagated the formation of functionally mature hepatocytes [129].  
Takebe et al. [130] demonstrated the formation of vascularised, functional human liver organoids from 
human iPSCs via transplantation of liver buds created in vitro (iPSCs-LB). The researchers were able to 
show the formation of functional vasculatures that stimulated the maturation of iPSC-LBs into tissue that 
highly resembled the adult liver. Metabolically competent iPSC-derived tissue demonstrated liver-specific 
functionality including increased albumin production and human-specific drug metabolism [130]. 
3D organoid systems provide an in vitro platform that is highly representative of the in vivo physiology of 
liver cells and have developed our understanding of disease development and progression. Liver organoids 
have also demonstrated accurate recapitulation of disease pathways in vivo. Although much of the research to 
date concerning liver organoid systems are focused on the developing field of personalised medicine, these 3D 
in vitro tools position themselves equally to be utilised within the field of xenobiotic safety and drug toxicity 
investigations.  
In vitro to in vivo extrapolation (IVIVE) 
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A number of in vitro cell models have been described within this review. However, it is becoming more 
apparent that quantitative analyses of the various in vitro liver models is necessary to aid in demonstrating 
their potential for hepatotoxicity investigations compared to more qualitative measures such as physiological 
and functional improvements of the cell models. Many reviews have detailed improved physiological and 
metabolic status of 3D and co-culture in vitro liver models. However, few have combined this with IVIVE as 
a quantitative classification tool for the different models.  IVIVE refers to the transposition of experimental 
results or data in vitro to predict phenomena in vivo. Extrapolation of intrinsic clearance (CLint) measurements 
using hepatocytes to give predicted in vivo clearance (CLin vivo) involves a well-established two-step 
mechanistic approach. Firstly, the physiological scaling from cell to whole liver and secondly the subsequent 
modelling of extraction from blood by the liver [22]. There have been a number of investigations that have 
compared in vitro liver model CLint as a means to develop the predictive capabilities with regards to 
xenobiotic safety assessments. 
Suspensions of PRH have been shown to provide a more accurate estimation of CLint rate when compared to 
conventional PRH monolayer cultures [131]. Griffin et al. [131] investigated the incubation of seven 
compounds in both suspensions and monolayer cultures, and the CLint was obtained via metabolite formation 
or substrate depletion analysis. However, the main limitation with this in vitro system was that cells rapidly 
dedifferentiated ex vivo in suspension, whereas often the processes of hepatotoxicity manifest themselves over 
several hours. Therefore, hepatocytes in suspension are unable to maintain viability for the time necessary for 
the development of toxicity for some xenobiotics. As such the assessment of long-term or repeat-dose 
investigations with this in vitro model will in turn be ineffectual.  
Research utilising rat microsomes, hepatocytes and liver slices have indicated adequate accuracy with the two-
step mechanistic approach [132]. However more recent investigations have demonstrated that rates of drug 
metabolism and CLint were found to be lower in rat liver slices than in isolated rat hepatocytes [133]. Other 
research has indicated that this two-step IVIVE mechanistic approach leads to under-prediction of human in 
vivo clearance when utilising human hepatocytes and microsomes [134].  
Although much of the work to date has particularly focused on suspensions and 2D cultures of cryopreserved 
and primary isolated hepatocytes, more recent publications have analysed the prospective competence of the 
more novel HepaRG hepatic-derived cells [135]. Zanelli et al. [135] compared intrinsic clearance of 26 drug 
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compounds in both cryopreserved hepatocytes and the more novel HepaRG cell line. The CLint of the 
compounds was determined via substrate depletion and results showed that there was a direct correlation of 
CLint for both cryopreserved hepatocytes and HepaRG cells (scaled to whole body) for the range of 
compounds used.  
Co-culture bioprinted systems have also been analysed to investigate their potential for hepatotoxity studies. 
An example of this is the Hepregen system which is a collagen micropatterned substrate system where 
hepatocytes are seeded onto a feeder layer of a secondary cell type. When compared to human microsomes, 
and PHH suspensions, the Hepregen system allowed for longer incubations with 27 known liver-metabolised 
compounds and was able to generate a greater proportion of the major human metabolites normally found in 
vivo [136]. 
Furthermore bioreactors and 3D cultures are rapidly becoming incorporated within industry and research as 
improved predictive platforms for xenobiotic safety assessments. Sivaraman et al [137] demonstrated this by 
using a 3D bioreactor system to analyse the functionality of PRH spheroids. This system was developed as it 
allowed the formation of heterotypic cell interactions, shear stresses via flow, and an in vivo liver-like 
microarchitecture. Toxicity testing utilising this bioreactor system included studies showing that clearance 
rates of compounds with known liver metabolism were comparable to those obtained in vivo [30,42].  
 
Summary  
There are a number of advantages that 3D in vitro liver models possess that place them well in the continually 
developing field of drug discovery and toxicological investigations. These models have been shown to  
demonstrate improved physiology, longevity and viability over extended culture periods, and increasing 
relevance when compared to classical monolayer cultures. Also, the ability to include multiple cell types 
within a single model has been shown to result in improved liver-specific functionality and longevity [38]. 
The continuing development of these in vitro liver models significantly improves their biological relevance 
and thus increases the chances that xenobiotic-induced toxicities, that require the complex interplay of a 
multicellular model, will be identified. 
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One of the main limitations of in vitro liver models, despite the recent advancements, is the inability to 
prolong the culture period for repeat-dose and long-term toxicological investigations, without extensive 
necrosis within the in vitro cellular environment. Most commonly used hepatic cell lines proliferate and as a 
result, microtissue models such a spheroids will increase in size. With an increase in functionality there seems 
to be an increase in oxygen consumption by the cells, and this increase in oxygen consumption coupled with 
excessive growth will inevitably result in the formation of necrotic regions within the model, greatly 
impacting on the phenotype of the model and the ability of oxygen and key nutrients to diffuse through the 3D 
culture.  
Primary cells have a number of advantages over the hepatic-derived cell lines including the inability to 
proliferate ex vivo and thus 3D cell models utilising these cells will remain relatively stable in size over time. 
In fact, it has been shown that primary hepatocytes cultured as spheroids actually contract over the culture 
period. The up-regulation of key ECM elements and cytoskeletal components causes and initial contraction of 
the spheroid body. It may be possible that over an extended culture period that cell viability may decrease, 
however, the ability of oxygen and key nutrients to diffuse through the spheroid is not interrupted. 
Table 2 shows the multiple cell types and model systems that are used to investigate liver toxicity in vitro, and 
defines the multiple advantages and disadvantages of these systems. It is clear from the literature that 2D and 
classic monolayer cultures of hepatic cell lines and primary hepatocytes are rapidly becoming superseded by 
the continually developing field of 3D, co-culture, bioreactor, and combined approaches. There is a wealth of 
research that has demonstrated that both 3D and co-culture approaches improve the liver-specific 
functionality, sensitivity to xenobiotics, culture longevity, recapitulation of the microenvironment and 
relevance to that of the in vivo liver, with 3D cell culture becoming the model of choice for many researchers 
and industrial institutions.  
Systems that utilise 3D cell culture that can incorporate flow dynamics for a primary cell type appear to hold 
the most promise for toxicological studies, due to that fact that many of the liver-specific functions remain 
stable over time along with the preservation of phase I, II and III genes associated with metabolism. In 
addition, models that incorporate multiple cell types, not limited to NPCs, have the ability to further enhance 
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the functional and predictive capabilities of the aforementioned 3D systems, through representative cells and 
cellular-ECM interactions.   
Outlook 
As the need for more predictive in vitro liver models increase, emerging 3D and bioreactor technologies have 
started to become increasingly utilised for xenobiotic hepatotoxicity assessments [138]. The incorporation of 
shear stress and flow has been demonstrated to improve functionality as described previously, and increases 
the complexity of the model system [50,51]. These more complex 3D and bioreactor technologies have the 
potential to capture some more of the intricate physiological aspects of the liver in vivo such as the solute and 
oxygen gradients of the liver sinusoid, and thus, may be able to better recapitulate the microenvironment of 
the native liver [7]. It has become clear that collaborative investigations between tissue engineers, 
toxicologist, applied mathematicians etc. whereby a more detailed assessment of the in vitro liver model set 
up is analysed, has focused the development of 3D and bioreactor models. While many of these systems show 
encouraging results, only a small number have provided extensive data that demonstrates the added value for 
hepatotoxicity investigations for human liver.  
Industry along with academia are continually developing a multitude of 3D in vitro liver models for 
toxicological investigations. Prior to these model systems being incorporated and utilised for early compound 
screening investigations, a pragmatic schedule of detailed evaluation and subsequent validation to show 
relevant pharmacological and toxicological end points is required. To date, liver organoids and spheroid 
models show good promise for assessment of hepatotoxicity, however they only partly recapitulate the native 
liver in vivo and so more complex flow systems, micro patterned plates and bioreactor technologies have 
started to emerge as other potential candidates.  
Furthermore, solute gradients, including oxygen, have been identified as key physiological characteristics that 
play a vital modulating role for liver zonation and subsequent gene expression and metabolism [98]. Recent 
focus of in vitro liver models has been directed at trying to capture these gradients in a physiological fashion. 
In the future, the screening for hepatotoxic potential of novel xenobiotics most likely requires a combined 
approach whereby multiple in vitro models to cover appropriate end points are needed. This approach 
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combined with the developing field of in silico liver models may better aid in early selection of compounds, 
and streamline the process by which toxicity investigations are carried out. 
In conclusion, multidisciplinary approaches in the development of more complex in vivo-like models will 
better aid human relevant translational research and will yield potential diagnostic advances that will reduce 
the risk of hepatotoxic potential at  pre-clinical and clinical levels. 
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Table 2. Advantages and limitations of currently used in vitro liver models. 
Cell Type Advantages Limitations 
   
 HepG2  
 
 
 
 
 
 
 
 
C3A (HepG2/C3A) 
 
 
 
 
 
 
HepaRG  
 
 
Unlimited source of cells. 
Repeatability of experiments is more 
achievable. 
Easy-to-handle in laboratory with 
simplistic culturing methods. 
No inter-donor differences. 
Some expression of liver-specific 
enzymes. 
 
Selected for strong contact inhibited 
growth characteristics. 
High albumin production, alpha 
fetoprotein (AFP) production and 
ability to thrive in glucose deficient 
media. 
 
Improved liver-specific functionality 
when compared with the commonly 
used HepG2 and C3A cells in 2D 
culture. 
More comparable to PHH for phase I 
& II, gene and transporter 
expression.  
Low metabolic competence and 
rapid loss of expression of 
liver-specific 
enzymes/transporters. 
Loss of cellular polarity.  
Absence of NPCs.  
 
 
 
Low metabolic competence and 
rapid loss of expression of 
liver-specific 
enzymes/transporters. Loss of 
polarity. 
Absence of NPC’s. 
 
More complex culturing 
methods when compared to 
more commonly used hepatic 
cell lines.  
Expensive consumables 
required for extended culture 
periods. Lack of NPCs. 
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Primary Hepatocytes (Human, Rat) 
 
Improved metabolic competence and 
more physiologically relevant 
compared to hepatic cell lines.  
Availability of cryopreserved 
hepatocytes. Full expression of liver-
specific enzymes.  
Good transferability of data for in 
vitro to in vivo models. Historical 
human data for numerous drugs 
allows for direct comparison with in 
vitro models.  
 
 
Limited availability for 
researchers and inter-donor 
variability.  
Short-term culture time. 
Rapid loss of expression of 
liver-specific enzymes.  
Unlike immortalised hepatic 
cell lines, hepatocytes do not 
proliferate in vitro. 
Difficult isolation and 
subsequent culturing processes.  
 
   
In-vitro Approaches  Advantages  Limitations   
   
 
2D  
 
 
 
 
 
Sandwich cultures  
 
 
 
 
Simplistic culture methods and low 
set-up costs.  Good repeatability of 
experimental data. Can incorporate  
NPC’s improving overall 
functionality and longevity. 
 
Sandwich cultured hepatocytes 
retain more in vivo-like properties, 
including polarised excretory 
function and enhanced morphology 
 
Doesn’t recapitulate complex 
3D microenvironment. 
Lack of in vivo-like cellular 
morphology. Poor protein 
expression profiles. 
 
Sandwich cultures lack 
complex cellular interactions 
and the 3D microenvironment. 
The expression of genes 
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3D 
 
 
 
 
 
 
 
 
Scaffold and hydrogel technology 
 
 
 
 
 
 
Co Culture  
and viability of hepatocytes 
compared to monolayer cultures.  
 
 
Recapitulation of 3D 
microenvironment and ECM 
properties. Well established cellular 
interactions leading to improved 
gene and protein expression. 
Establishment of cellular polarity.  
Can incorporate NPC’s improving 
overall functionality and longevity. 
 
Formation of cellular interactions 
and representation of native ECM. 
Improved functionality and 
sensitivity to APAP. 
 
 
 
Multi-cellular environment with 
direct cell-cell interactions 
mimicking natural environment. 
Positive reciprocal effect with 
improved functionality and 
longevity.  
Co-culture models can be produced 
responsible for many liver-
specific functions decreases 
over time. 
 
More complicated methods of 
culture. The literature has 
extensively discussed the 
formation of necrotic regions 
within 3D cellular models due 
to reduced oxygen diffusion to 
cells within the 3D mass. 
 
 
Limitations with regards to 
mass transfer 
(oxygen/nutrients). Difficult for 
cell retrieval and subsequent 
analysis. Poor culture 
longevity.  
 
Limited availability of NPCs 
with difficult isolation 
procedures.  
Like primary hepatocytes, 
NPCs are unable to proliferate 
in vitro. 
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in 2D and sandwich cultures and also 
within 3D cultures such as 
spheroids. Recovery of cellular 
polarity.  
 
Liver Slices  
 
 
 
 
 
Spheroids  
Maintains multicellularity (all 
NPC’s) in appropriate proportions 
and complex 3D microenvironment. 
Can be incorporated into flow 
systems to allow shear stresses. 
 
Multicellular environments 
recapitulating native 3D 
microenvironment. Cell-cell 
interactions and natural production 
of ECM. Spheroids can be produced 
with hepatic cell lines and primary 
hepatocytes.  
Maintain liver-specific functionality 
over longer periods of time. 
Enhanced CYP450 and transporter 
expression.  
Formation of secondary structures 
(bile canalicular-like structures).  
Cellular polarity is recovered. Along 
with maintenance of native cuboidal 
morphology. 
Short term culture periods 
meaning liver slices are 
unsuitable for repeat-dose 
investigations. 
 
 
Spheroids have a limited size 
due to formation of necrotic 
cores (~150μm). Limitations of 
oxygen and nutrient diffusion 
through multicellular 
aggregates. Comprehensive 
investigation with regards to 
optimal spheroid size for 
specifics cell types has yet to be 
done including cell-specific and 
model-specific OUR. 
More work needs to be done to 
improve basis for high-
throughput system.  
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